A new “ultra-sensitive” blood test developed by researchers in the United Kingdom can detect signs of breast cancer recurrence up to 41 months before the disease shows up on imaging scans — a finding experts are calling one of the most promising early-detection advances in years. In a small but striking trial, the test predicted every single relapse with 100% accuracy, raising real hope for earlier intervention and better survival outcomes.
At a glance
- Liquid biopsy: The blood test scans for 1,800 cancer-related mutations circulating in a patient’s bloodstream — fragments of tumour DNA shed by cancer cells that linger in the body after surgery and treatment.
- Breast cancer recurrence: In the trial of 78 patients, circulating tumour DNA was detected in 11 women, all of whom later relapsed — and no other participants saw their cancer return, suggesting remarkable precision.
- Early detection window: On average, the test identified returning cancer 15 months before symptoms appeared or scans confirmed it, with the earliest detection coming a full 41 months ahead of a confirmed diagnosis.
Why this matters
Breast cancer is the most common cancer in the world. According to Breast Cancer UK, 2.26 million women were diagnosed in 2020 C.E. and 685,000 died from the disease that same year. Even when initial treatment appears successful, cancer cells can persist in the body at levels too low for conventional scans to detect — then re-emerge years later.
That gap between hidden recurrence and visible relapse has long been one of oncology’s most frustrating blind spots. This test targets it directly.
“Breast cancer cells can remain in the body after surgery and other treatments, but there can be so few of these cells that they are undetectable on follow-up scans,” said lead researcher Dr. Isaac Garcia-Murillas of the Institute of Cancer Research (ICR) London. He noted that those dormant cells can trigger relapse many years after a patient finishes treatment.
How the test works
The trial enrolled 78 patients with different types of early breast cancer. Researchers drew blood at the point of diagnosis, then again after surgery and chemotherapy. Follow-up tests were repeated every three months for a year, then every six months for five years — building a detailed picture of how each patient’s tumour DNA behaved over time.
The results were presented at the American Society of Clinical Oncology annual conference in Chicago. They have not yet been published in a peer-reviewed journal, and the trial size — while encouraging — is small. Larger studies will be needed before the test can move toward clinical use.
What could change for patients
The practical implications are significant. When breast cancer is caught at an early or locally recurrent stage, treatment is far more likely to eliminate it before it spreads to other organs and becomes harder to control. In the U.K. alone, around 11,000 people die every year from secondary — or metastatic — breast cancer, according to Breast Cancer Now, which part-funded the study.
Dr. Simon Vincent, Breast Cancer Now’s director of research, support and influencing, called the findings “incredibly exciting,” adding that catching recurrence earlier means treatment is “much more likely to destroy the cancer and stop it spreading.”
Garcia-Murillas said the study lays the groundwork for better post-treatment monitoring and potentially life-extending therapy — giving oncologists a longer runway to act before a patient’s health deteriorates.
Still early, but pointing somewhere important
It is not yet clear when the test could become widely available, and researchers are candid that this work is at an early stage. The 78-person trial, however promising, will need to be replicated at scale across more diverse patient populations before the findings can be considered definitive.
The result adds to a broader wave of progress in liquid biopsy research, where blood-based tests are being explored across multiple cancer types. The idea that a simple blood draw could one day replace or supplement expensive imaging — and do so earlier and more accurately — is no longer speculative. Studies like this one are moving it steadily toward reality.
Read more
For more on this story, see: BBC News
For more from Good News for Humankind, see:
- U.K. cancer death rates drop to their lowest level on record
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
